Insulet Corporation (PODD) is currently under
fraud investigation by Schall Law Firm, as well as other legal entities, due to potential
securities fraud linked to alleged safety misrepresentations by its executives. In response to company rumors of a concealed device defect, legal firms are urging investors with losses to consider leading class actions lawsuits. Amid these challenges, various companies are repositioning their investments in Insulet.
Diversified Trust Co., Assenagon Asset Management S.A., and Gradient Investments LLC are among the entities that recently purchased substantial amounts of shares, while others like Swiss National Bank, JPMorgan Chase & Co., and Capital Research Global Investors sold their shares. Meanwhile, Insulet stock performance remained mixed as it saw both bullish views and significant share pullbacks. Investors are also concerned about the
Omnipod 5 device correction, which might cost up to $40 million, affecting other stock holders' decisions. Lastly, despite the company's shares lagging, Insulet continues to test its closed loop pod for type 2 diabetes.
Insulet Corporation PODD News Analytics from Mon, 15 Sep 2025 07:00:00 GMT to Sat, 28 Mar 2026 19:27:33 GMT -
Rating -5
- Innovation 0
- Information 1
- Rumor -7
